Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia

NCT04245722 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT04245722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04245722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
Lead sponsor
Fate Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
March 19, 2020
Completion date
September 27, 2023
Enrollment
98 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, lymphoma, b-cell